ARG23182

anti-CD16.2 / FcgRIV antibody [AT137] (FITC)

anti-CD16.2 / FcgRIV antibody [AT137] (FITC) for Flow cytometry and Mouse

Overview

Product Description FITC-conjugated Rat Monoclonal antibody [AT137] recognizes CD16.2 / FcgRIV
Mouse anti human CD16-2 antibody, clone AT137, recognizes CD16-2, also known as FcRIV. CD16-2 is a low affinity activatory receptor that binds to IgG2a and IgG2b with intermediate affinity. FcRIV has no affinity for IgG1 or IgG3 and therefore has a unique subclass specificity when compared to other Fc receptors. Expression of CD16-2 is restricted to cells of the myeloid lineage.
Tested Reactivity Ms
Tested Application FACS
Host Rat
Clonality Monoclonal
Clone AT137
Isotype IgG2a
Target Name CD16.2 / FcgRIV
Antigen Species Mouse
Immunogen Fusion Protein consisting of mouse CD16-2 and rat CD4.
Conjugation FITC
Alternate Names Fcrl3; CD16-2; FcgRIV; Fcgr3a; FcgammaRIV; 4833442P21Rik

Application Instructions

Application Suggestion
Tested Application Dilution
FACSNeat - 1:10
Application Note FACS: Use 10 µl of the suggested working dilution to label 10^6 cells in 100 µl.
* The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.

Properties

Form Liquid
Purification Purification with Protein G.
Buffer PBS, 0.09% Sodium azide and 1% BSA.
Preservative 0.09% Sodium azide
Stabilizer 1% BSA
Concentration 0.1 mg/ml
Storage Instruction Aliquot and store in the dark at 2-8°C. Keep protected from prolonged exposure to light. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use.
Note For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Gene Symbol Fcgr4
Gene Full Name Fc receptor, IgG, low affinity IV
Function Receptor for the Fc region of immunoglobulin gamma (PubMed:16039578). Also acts as a receptor for the Fc region of immunoglobulin epsilon (PubMed:17558411, PubMed:18949059). Binds with intermediate affinity to both IgG2a and IgG2b (PubMed:16039578, PubMed:17558411, PubMed:19795417). Can bind to IgG2a and IgG2b monomers (PubMed:18949059). Does not display binding to IgG1 or IgG3 (PubMed:16039578). Mediates neutrophil activation by IgG complexes redundantly with Fcgr3 (PubMed:18097064). Plays a role in promoting bone resorption by enhancing osteoclast differentiation following binding to IgG2a (PubMed:25824719). Binds with low affinity to both the a and b allotypes of IgE (PubMed:18949059). Has also been shown to bind to IgE allotype a only but not to allotype b (PubMed:17558411). Binds aggregated IgE but not the monomeric form and bound monomeric IgG is readily displaced by IgE complexes (PubMed:18949059). Binding to IgE promotes macrophage-mediated phagocytosis, antigen presentation to T cells, production of proinflammatory cytokines and the late phase of cutaneous allergic reactions (PubMed:17558411, PubMed:18949059). [UniProt]
Calculated MW 28 kDa